Birthweight in pregnant women with protein S deficiency treated with low-molecular-weight heparin: a retrospective cohort study

References

• Jarvis S, Glinianaia SV, Torrioli MG, et al. Surveillance of Cerebral Palsy in Europe (SPCE) collaboration of European Cerebral Palsy. Cerebral palsy and intrauterine growth in single births: European collaborative study. Lancet 2003;362:1106–11
   PubMed Web of Science ®Google Scholar
• Leitner Y, Fattal-Valevski A, Geva R, et al. Neurodevelopmental outcome of children with intrauterine growth retardation: a longitudinal, 10-year prospective study. J Child Neurol 2007;22:580–7
   PubMed Web of Science ®Google Scholar
• Resnik R. Intrauterine growth restriction. Obstet Gynecol 2002;99:490–6
   PubMed Web of Science ®Google Scholar
• Godfrey KM, Barker DJ. Fetal nutrition and adult disease. Am J Clin Nutr 2000;71:1344S–52S
   PubMed Web of Science ®Google Scholar
• Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999;340:9–13
   PubMed Web of Science ®Google Scholar
• Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb Res 2003;109:73–81
   PubMed Web of Science ®Google Scholar
• Brenner B. Inherited thrombophilia and poor pregnancy outcome. Best Pract Res Clin Obstet Gynecol 2003;17:427–39
   PubMed Web of Science ®Google Scholar
• Robertson L, Wu O, Langhorne P, et al. Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006;132:171–96
   PubMed Web of Science ®Google Scholar
• Kosar A, Kasapoglu B, Kalyoncu S, et al. Treatment of adverse perinatal outcome in inherited thrombophilias: a clinical study. Blood Coagul Fibrinolysis 2011;22:14–8
   PubMed Web of Science ®Google Scholar
• Said JM, Higgins JR, Moses EK, et al. Inherited thrombophilias and adverse pregnancy outcomes: a case–control study in an Australian population. Acta Obstet Gynecol Scand 2012;91:250–5
   PubMed Web of Science ®Google Scholar
• Lundwall A, Dackowski W, Cohen E, et al. Isolation and sequence of the cDNA for human protein S, a regulator of blood coagulation. Proc Natl Acad Sci USA 1986;83:6716–20
   PubMed Web of Science ®Google Scholar
• De Bonis M, Sabatini L, Galeazzi LR, et al. Maternal serum protein S forms in pregnancies complicated by intrauterine growth restriction. Eur J Obstet Gynecol Reprod Biol 2012;160:142–6
   PubMed Web of Science ®Google Scholar
• Paidas MJ, Ku DH, Lee MJ, et al. Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications. J Thromb Haemost 2005;3:497–501
   PubMed Web of Science ®Google Scholar
• Hojo S, Tsukimori K, Kinukawa N, et al. Decreased maternal protein S activity is associated with fetal growth restriction. Thromb Res 2008;123:55–9
   PubMed Web of Science ®Google Scholar
• Mirzaei F, Farzad-Mahajeri Z. Association of hereditary thrombophilia with intrauterine growth restriction. Iran J Reprod Med 2013;11:275–8
   PubMedGoogle Scholar
• Rodger MA, Walker MC, Smith GN, et al. Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. J Thromb Haemost 2014;12:469–78
   PubMed Web of Science ®Google Scholar
• de Vries JI, van Pampus MG, Hague WM, et al. FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost 2012;10:64–72
   PubMed Web of Science ®Google Scholar
• Fernández Alba JJ, Martín A, Torrejón R, et al. Sistema de informatización de la Unidad de Partos del Hospital Universitario de Puerto Real. Prog Obstet Ginecol 1995;38:297–308
   Google Scholar
• Wolf M, Boyer-Neumann C, Martinou JL, et al. A new functional assay for human protein S activity using activated factor V as substrate. Thromb Haemost 1989;62:1144–5
   PubMed Web of Science ®Google Scholar
• Mayer C, Joseph KS. Fetal growth: a review of terms, concepts and issues relevant to obstetrics. Ultrasound Obstet Gynecol 2013;41:136–45
   PubMed Web of Science ®Google Scholar
• Fernández-Alba JJ, González-Macías C, León Del Pino R, et al. Customized versus population-based birth weight references for predicting fetal and neonatal undernutrition. Fetal Diagn Ther 2016;39:198–208
   PubMed Web of Science ®Google Scholar
• Alferivic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002;101:6–14
   PubMed Web of Science ®Google Scholar
• Gris JC, Mercier E, Quéré I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004;103:3695–9
   PubMed Web of Science ®Google Scholar
• Greer I. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999;353:1258–65
   PubMed Web of Science ®Google Scholar
• Greer I, Hunt BJ. Low molecular weight heparin in pregnancy: current issues. Br J Haematol 2005;128:593–601
   PubMed Web of Science ®Google Scholar
• Omri A, Delaloye JF, Andersen H, Bachmann F. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost 1989;61:55–6
   PubMed Web of Science ®Google Scholar
• Deruelle P, Coulon C. The use of low-molecular-weight heparins in pregnancy-how safe are they? Curr Opin Obstet Gynecol 2007;19:573–7
   PubMed Web of Science ®Google Scholar
• Aracic N, Roje D, Drmic Hofman I, et al. Low molecular weight heparin treatment and impact of inherited thrombophilia type in pregnancies with previous adverse outcome. J Matern Fetal Neonatal Med 2015;28:306–10
   PubMed Web of Science ®Google Scholar
• Conserva V, Muggiasca M, Arrigoni L, et al. Recurrence and severity of abnormal pregnancy outcome in patients treated by low-molecular-weight heparin: a prospective pilot study. J Matern Fetal Neonatal Med 2012;25:1467–73
   PubMed Web of Science ®Google Scholar
• Kupferminc M, Rimon E, Many A, et al. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia. Blood Coagul Fibrinolysis 2011;22:123–6
   PubMed Web of Science ®Google Scholar
• Yinon Y, Ben Meir E, Margolis L, et al. Low molecular weight heparin therapy during pregnancy is associated with elevated circulatory levels of placental growth factor. Placenta 2015;36:121–4
   PubMed Web of Science ®Google Scholar
• Wang L, Brown JR, Varki A, Esko JD. Heparin’s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002;110:127–36
   PubMed Web of Science ®Google Scholar
• Oberkersch R, Attorresi AI, Calabrese GC. Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy. Thromb Res 2010;125:e240–5
   PubMed Web of Science ®Google Scholar